Raymond James & Associates Buys 1,125 Shares of Fresenius Medical Care AG (NYSE:FMS)

Raymond James & Associates lifted its stake in Fresenius Medical Care AG (NYSE:FMS) by 4.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,960 shares of the company’s stock after purchasing an additional 1,125 shares during the period. Raymond James & Associates’ holdings in Fresenius Medical Care were worth $603,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Signaturefd LLC grew its holdings in Fresenius Medical Care by 7.3% during the 3rd quarter. Signaturefd LLC now owns 8,601 shares of the company’s stock worth $185,000 after acquiring an additional 584 shares in the last quarter. Morningstar Investment Services LLC grew its holdings in Fresenius Medical Care by 6.4% during the 3rd quarter. Morningstar Investment Services LLC now owns 10,145 shares of the company’s stock worth $220,000 after acquiring an additional 612 shares in the last quarter. National Bank of Canada FI grew its holdings in Fresenius Medical Care by 4.4% during the 3rd quarter. National Bank of Canada FI now owns 20,236 shares of the company’s stock worth $427,000 after acquiring an additional 845 shares in the last quarter. Bruce G. Allen Investments LLC bought a new position in Fresenius Medical Care during the 4th quarter worth about $31,000. Finally, First Trust Direct Indexing L.P. grew its holdings in Fresenius Medical Care by 6.6% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 23,888 shares of the company’s stock worth $515,000 after acquiring an additional 1,482 shares in the last quarter. 8.25% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on FMS shares. StockNews.com started coverage on shares of Fresenius Medical Care in a report on Friday. They set a “strong-buy” rating on the stock. Morgan Stanley cut shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a report on Monday, January 8th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $32.25.

Fresenius Medical Care Stock Down 2.6 %

NYSE:FMS opened at $20.23 on Friday. Fresenius Medical Care AG has a fifty-two week low of $16.37 and a fifty-two week high of $27.72. The stock has a market capitalization of $11.87 billion, a P/E ratio of 21.98, a P/E/G ratio of 1.18 and a beta of 1.00. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.07 and a current ratio of 1.42. The company’s 50-day simple moving average is $19.53 and its 200-day simple moving average is $19.47.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings results on Tuesday, February 20th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.11. The business had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.32 billion. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. On average, equities analysts anticipate that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The business also recently announced an annual dividend, which will be paid on Monday, June 3rd. Investors of record on Monday, May 20th will be paid a $0.437 dividend. This represents a yield of 2.35%. The ex-dividend date of this dividend is Friday, May 17th. Fresenius Medical Care’s dividend payout ratio (DPR) is presently 45.65%.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.